Abevmy market forecast points to strong long-term biosimilar growth

The Business Research Company says the Abevmy market is set for notable growth through 2035 as cancer cases rise and health systems push for lower-cost oncology treatments. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - Abevmy is a biosimilar cancer treatment, and demand for lower-cost oncology drugs is rising as cancer rates increase worldwide. - Growth in biosimilars could ease treatment costs for hospitals, payers and patients facing expensive biologic cancer therapies. - The market outlook signals more room for bevacizumab biosimilars in settings where cost pressure is high.

What happened: - The Business Research Company released its Abevmy Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the Abevmy market is gaining attention because of rising cancer cases and shifting healthcare policies. - The report defines Abevmy as a biosimilar version of bevacizumab used in cancer treatment. - A free sample of the report is available. - The full market report is also available.

The details: - Historical growth was driven by the high cost of original biologic drugs, rising global cancer incidence, VEGF inhibition therapy effectiveness, broader hospital use of oncology drugs and early biosimilar regulatory frameworks. - Forecast growth is tied to wider biosimilar use in oncology, higher demand for cost-effective cancer treatment, stronger government support, more cancer patients and broader tender-based procurement. - The report expects key trends to include greater adoption of bevacizumab biosimilars, more use in cost-sensitive cases, hospital-led switching to biosimilars, expansion of anti-angiogenic therapies and stronger regulatory support for approvals. - Abevmy targets vascular endothelial growth factor, or VEGF, which helps tumors form blood vessels that supply oxygen and nutrients. - By blocking VEGF, Abevmy limits angiogenesis and can slow tumor growth and spread. - The report cites cancer prevalence as a key driver and points to lifestyle factors, aging populations, diet, inactivity, smoking, alcohol use and carcinogen exposure as contributors. - In February 2025, the American Cancer Society projected about 9,550 new cancer cases in US children ages 0 to 14 and 5,140 in adolescents ages 15 to 19, with about 1,050 child deaths and 600 adolescent deaths. - North America held the largest Abevmy market share in 2025, supported by advanced healthcare infrastructure and high biosimilar adoption. - Asia-Pacific is projected to grow fastest during the forecast period because of expanding healthcare access and rising cancer diagnoses. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, key technology and future trend analysis, and updated graphics and tables.

Between the lines: - The report frames Abevmy as part of a broader biosimilar shift in oncology, where pricing and procurement strategies matter as much as clinical performance. - Hospital-led switching and tender-based buying suggest purchasing decisions may continue to shape biosimilar uptake more than brand loyalty. - The emphasis on regulatory support indicates approvals and reimbursement policy will remain central to market expansion.

What's next: - The report expects biosimilar penetration in oncology to deepen over the forecast period. - More health systems are likely to adopt tender-based procurement for cancer drugs. - Future market gains will likely track cancer incidence, policy support and access improvements in emerging regions. - Company contact information and social links were included in the release for readers seeking more details about the report.